
Common household chemical found linked to heart disease deaths
Daily exposure to chemicals used in common household plastic products could be behind hundreds of thousands of heart disease -related deaths every year, according to a new study.
Scientists have long warned of health problems linked to this class of plastic chemicals called phthalates, typically found in cosmetics, detergents, solvents, plastic pipes, and bug repellants.
Previous studies have linked the chemicals to increased risks of obesity, diabetes, hormone and fertility issues, and cancer.
Now, a new study has linked the plastic ingredient to more than 356,000 global deaths from heart disease in 2018 alone.
Researchers from New York University Langone Health studied Di-2-ethylhexyl phthalate, or DEHP, which is used to make food containers, medical equipment, and other plastic products softer and more flexible, and found that prolonged exposure to the chemical could cause inflammation in the arteries of the heart, which, over time, could heighten heart attack or stroke risk.
The latest study, published in the journal EBio Medicine, found that DEHP exposure contributed to 356,238 deaths in 2018, nearly 13 per cent of all global mortality from heart disease among men and women aged between 55 and 64 that year.
Researchers estimated the economic burden from the deaths at around $510 billion but noted that it could reach as high as $3.74 trillion.
'By highlighting the connection between phthalates and a leading cause of death across the world, our findings add to the vast body of evidence that these chemicals present a tremendous danger to human health,' study co-author Sara Hyman said.
In the study, scientists assessed health and environmental data from dozens of population surveys to estimate DEHP exposure across 200 countries and territories. The data also included urine samples containing chemical breakdown products left by the plastic additive.
India had the highest death toll linked to phthalates at 103,587, followed by China and Indonesia, the study concluded.
Scientists suspect the high mortality linked to DEHP exposure in these countries could be due to a boom in their plastic production but with fewer manufacturing restrictions than in other regions.
'There is a clear disparity in which parts of the world bear the brunt of heightened heart risks from phthalates,' study senior author Leonardo Trasande said.
While researchers cautioned that the findings did not imply DEHP caused heart disease directly or alone, they said the overall death toll from heart disease connected to these chemicals could be much higher.
'Our results underscore the urgent need for global regulations to reduce exposure to these toxins, especially in areas most affected by rapid industrialization and plastic consumption,' Dr Trasande said.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Geeky Gadgets
21 minutes ago
- Geeky Gadgets
How MedGemma Open Source AI is Making Cutting-Edge Healthcare Accessible to All
What if the future of healthcare didn't depend on expensive, proprietary systems but instead thrived on a foundation of openness and collaboration? Imagine a world where innovative medical tools are accessible to rural clinics as easily as they are to urban hospitals, where AI-driven diagnostics and treatment planning are no longer luxuries but standard practice. This is the bold promise of MedGemma, an open source model that's rewriting the rules of medical innovation. By combining the power of artificial intelligence with the adaptability of open source technology, MedGemma is not just a tool—it's a movement toward a more equitable and efficient healthcare system. In this exploration of MedGemma, Sam Witteveen uncovers how this innovative platform is providing widespread access to healthcare by breaking down barriers of cost, geography, and expertise. From its ability to enhance critical medical decision-making to its role in streamlining hospital operations and advancing clinical research, MedGemma's versatility is reshaping the way we think about healthcare delivery. But what makes this model truly fantastic is its collaborative nature, inviting contributions from a global network of experts to ensure it evolves alongside medical science. As we delve deeper, you'll discover how MedGemma is not just addressing today's challenges but also laying the groundwork for a future where healthcare innovation knows no bounds. MedGemma: Open Source Healthcare AI The Importance of Open source in Healthcare Open source technology forms the foundation of MedGemma, offering unparalleled transparency, collaboration, and adaptability. Unlike proprietary systems, open source models empower developers and healthcare professionals to tailor tools to meet specific needs. This flexibility is particularly critical in healthcare, where diverse challenges often require customized solutions. MedGemma's open framework invites contributions from a global network of experts, making sure the model evolves in tandem with advancements in medical science. By using open source principles, MedGemma promotes a culture of shared knowledge and innovation. This collaborative approach not only accelerates technological progress but also ensures that the tools remain relevant and effective in addressing emerging healthcare challenges. The adaptability of open source systems like MedGemma makes them indispensable in a field where precision and reliability are paramount. AI Integration: Enhancing Medical Decision-Making MedGemma integrates artificial intelligence (AI) to transform medical decision-making processes. By analyzing vast datasets, it supports critical tasks such as diagnostics, treatment planning, and patient monitoring. For example, MedGemma can process medical images to identify abnormalities, predict disease progression based on patient history, or even recommend personalized treatment options. These AI-driven capabilities not only enhance the accuracy of medical decisions but also reduce the likelihood of human error in high-stakes situations. The use of AI in MedGemma extends beyond diagnostics. It enables healthcare providers to identify trends in patient data, optimize resource allocation, and improve overall operational efficiency. By combining AI with an open source framework, MedGemma ensures that these advanced tools remain accessible and adaptable, empowering medical professionals to deliver better care. MedGemma : An Open Doctor Model? Watch this video on YouTube. Find more information on open source AI models by browsing our extensive range of articles, guides and tutorials. Applications Across Healthcare Domains MedGemma's versatility makes it a valuable asset across various sectors of healthcare. Its applications include: Hospital Operations: Automating administrative tasks such as patient record management, appointment scheduling, and resource allocation to improve efficiency. Automating administrative tasks such as patient record management, appointment scheduling, and resource allocation to improve efficiency. Clinical Research: Accelerating the analysis of clinical trial data, allowing researchers to identify patterns, validate hypotheses, and develop innovative treatments more quickly. Accelerating the analysis of clinical trial data, allowing researchers to identify patterns, validate hypotheses, and develop innovative treatments more quickly. Telemedicine: Facilitating remote consultations and improving access to healthcare for underserved populations, particularly in rural or resource-limited areas. Facilitating remote consultations and improving access to healthcare for underserved populations, particularly in rural or resource-limited areas. Diagnostics: Assisting in the early detection of diseases through advanced image analysis and predictive modeling. This adaptability ensures that MedGemma can address the unique needs of diverse healthcare environments, from large urban hospitals to small rural clinics. Its ability to integrate seamlessly into existing systems further enhances its utility, making it a practical choice for healthcare providers worldwide. Accessibility: Breaking Down Barriers MedGemma's commitment to accessibility is a defining feature. As an open source platform, it eliminates the financial barriers often associated with proprietary medical tools, making advanced technology available to healthcare providers regardless of their budget. This is particularly impactful in low-resource settings, where access to innovative tools can significantly improve patient outcomes. Additionally, MedGemma's user-friendly design ensures that it can be implemented with minimal technical expertise. This ease of use is crucial in environments where specialized training may not be readily available. By prioritizing accessibility, MedGemma not only reduces global healthcare disparities but also enables providers to deliver high-quality care in even the most challenging circumstances. Reliability in Critical Healthcare Scenarios In the healthcare sector, reliability is non-negotiable. MedGemma is designed to meet the highest standards of performance, making sure consistent results across a variety of medical scenarios. Rigorous testing and validation processes underpin its development, guaranteeing that it functions reliably even in high-pressure environments. The open source nature of MedGemma further enhances its reliability. Peer reviews and contributions from a global community of developers and medical experts ensure that the platform remains robust and up-to-date. This collaborative approach fosters trust in its capabilities, allowing healthcare professionals to focus on patient care with confidence in the tools they are using. Driving Innovation and Collaboration MedGemma exemplifies the fantastic potential of open source innovation in healthcare. By combining AI with a collaborative development model, it addresses critical challenges such as accessibility, adaptability, and reliability. Its applications span diagnostics, research, patient care, and operational efficiency, making it an indispensable resource for medical professionals and researchers alike. As the healthcare industry continues to embrace technology, models like MedGemma will play a pivotal role in shaping a more equitable and efficient future. By fostering a culture of collaboration and shared knowledge, MedGemma not only enhances existing healthcare systems but also lays the groundwork for future innovations that prioritize patient well-being and global health equity. Media Credit: Sam Witteveen Filed Under: AI, Top News Latest Geeky Gadgets Deals Disclosure: Some of our articles include affiliate links. If you buy something through one of these links, Geeky Gadgets may earn an affiliate commission. Learn about our Disclosure Policy.


The Independent
an hour ago
- The Independent
When does Alien Earth drop? Everything to know about the new sci-fi series
Something gross is coming to our screens. Landing on 13 August, the first two episodes of the upcoming sci-fi horror series Alien:Earth will be available to stream on Disney+. A prequel to Ridley Scott's 1979 Alien, there will be eight episodes landing in total, with the first two premiering on the release date, and new episodes dropping every Wednesday. The first TV series of the Alien franchise, Alien:Earth is set in the year 2120. Wendy, played by Don't Worry Darling's Sydney Chandler, breaks new ground as the first humanoid robot with human consciousness. But when an extraterrestrial vessel crashes into Earth, Wendy and a team of soldiers go looking for signs of life and find something terrible within. No prizes for guessing what that is. While we have a couple of months before the series lands, the official trailer teases some of the plot points. The most chilling quote in the trailer is that 'The ship collected five different life forms from the darkest corners of the universe.' It's terrifying to think, but it seems the team will have to tackle more than just the xenomorph we know from the Alien franchise. On the creative and production team is Noah Hawley (the screen writer behind major series including Fargo and Legion), Ridley Scott, David W. Zucker, Joseph Iberti, Dana Gonzales and Clayton Krueger, while cast members include Alex Lawther from The End of the F***ing World and Black Mirror, Kit Young from The Beautiful Game, Timothy Olyphant from Fargo and The Mandalorian), The Babadook's Essie Davis, and Adarsh Gourav from White Tigers. Where can I watch Alien: Earth in the UK? While the series will premiere on August 12 on FX and Hulu in the US, it will launch in the UK and Ireland on 13 August on Disney+. When it premieres, we'll get two episodes, then episodes will drop every Wednesday. How to sign up for Disney+ Disney+ is a paid subscription and costs £4.99 per month. Unlike Amazon and some other streaming services, there isn't a free trial, which means you need to commit to one month of the service, but it's worth keeping in mind that you can cancel your subscription at any time. That said, you might not want to. Disney+ is home to some of the most talked-about shows at the moment, such as The Bear and Star Wars series, Andor. There's also a host of family favourites, such as The Simpsons and animated Disney films from Frozen to Encanto.


Telegraph
2 hours ago
- Telegraph
The cheap fat jabs sending big pharma into a frenzy
For many Americans who tuned in to watch the Super Bowl earlier this year, it was a surprise to find themselves fat-shamed during the ad break. 'Obesity is America's deadliest epidemic,' a voiceover said, as images of wobbling bellies, greasy burgers and giant apple pies flashed across TV screens. The Super Bowl's 127m-strong audience, who were tucking into an estimated 1.5bn chicken wings during the event, were warned that 'obesity leads to half a million deaths each year'. But Hims and Hers, the US online medicines company behind the ad, said people should not blame themselves. Instead, its advert claimed that 'the system' was keeping them 'sick and stuck', adding that 'there are medications that work, but they're priced for profits, not patients'. To the relief of viewers, Hims and Hers offered a 'life-changing' solution. Rather than paying hundreds of dollars each month for well-known, branded weight-loss jabs such as Wegovy, households could instead try Hims and Hers' cheaper, replica versions. 'This is the future of healthcare,' it argued. 'Join us in the fight for a healthier America.' However, for the likes of Danish obesity drug maker Novo Nordisk and US pharma rival Eli Lilly, which have claimed the rise of copycat jabs poses potential health risks, such claims have become a serious headache. Copycat boom Over the past few decades, both businesses have poured billions of dollars into obesity drug research – recently yielding blockbuster drugs Wegovy and Mounjaro. The rapid uptake of such drugs has prompted a surge in revenues for big pharma. But bosses are now increasingly worried that demand among American patients has been dented by a cluster of smaller, copycat companies.